+44 1223 790975
Department of Pharmaceutical Sciences
Thomas Jefferson University, USA
Dr. Takemi Tanaka expertisation covers a broad area of cancer research including chemoprevention, targeted therapy, and cancer nanomedicine. During his Postdoctoral period, he have investigated detailed molecular mechanisms of the anti-cancer effect of nuclear hormone receptors in carcinogenesis in breast cancer. To further expand his research expertise in nanotechnology and drug delivery, he had an additional experience as a Research Assistant Professor at The University of Texas Houston, medical school and developed Delivery Strategies for tumor targeting and sustained delivery. He was recruited as a Tenure Track Assistant Professor at the Thomas Jefferson University in conjunction with Kimmel Cancer Center in 2010. He is also a faculty member of the KCC Endocrine Mechanisms and Hormone Action in Cancer Program, which focus on breast cancer signaling and etiology. Nanotechnology is an emerging area of research that can potentially bring a major breakthrough in the detection and therapy for cancer. Based on the given number of nanotechnology based clinical trials that are underway.